AEGEAN Trial: Perioperative Durvalumab & ctDNA Clearance in Resectable NSCLC – WCLC/ESMO 2024

33 Visioni
Published
This video covers key updates from the phase 3 AEGEAN trial presented at WCLC 2024 and ESMO 2024, focusing on perioperative durvalumab in resectable NSCLC and the expanded analysis of circulating tumor DNA (ctDNA) clearance during neoadjuvant treatment.

???? Stay informed with the latest evidence in immunotherapy and precision oncology.

#AEGEANTrial #Durvalumab #NSCLC #WCLC2024 #ESMO2024 #ctDNA #LungCancer #Immunotherapy
Categoria
Oncology
Commenta per primo questo video.